Handok
As of the edition of 20 October 2026, Handok runs 5 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Stopped | 2 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Asciminib | Ends 2040 (patent) | 0 |
| Teneligliptin | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Hormones: 11 trials led
- Nutrition and metabolism: 11 trials led
- Immune system: 2 trials led